标题
Targeting HER2-positive breast cancer: advances and future directions
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 22, Issue 2, Pages 101-126
出版商
Springer Science and Business Media LLC
发表日期
2022-11-08
DOI
10.1038/s41573-022-00579-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
- (2022) Aileen I. Fernandez et al. JAMA Oncology
- Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
- (2022) Aleix Prat et al. EBioMedicine
- LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
- (2022) M.F. Mosele et al. ANNALS OF ONCOLOGY
- 165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
- (2022) R. Bartsch et al. ANNALS OF ONCOLOGY
- Abstract P5-13-32: Mucin 4 expression in high risk breast cancer: Predicting and overcoming resistance to immunotherapy
- (2022) Roxana Schillaci et al. CANCER RESEARCH
- Abstract P2-13-45: Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors
- (2022) Brian A. Van Tine et al. CANCER RESEARCH
- Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer
- (2022) Jamunarani Veeraraghavan et al. CANCER RESEARCH
- Abstract P2-13-43: Preclinical and early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer
- (2022) Jian Zhang et al. CANCER RESEARCH
- Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models
- (2022) Sreyashree Bose et al. CANCER RESEARCH
- Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
- (2022) Philippe L Bedard et al. CANCER RESEARCH
- Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
- (2022) Sandra M. Swain et al. CANCER TREATMENT REVIEWS
- Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
- (2022) Fan Shi et al. DRUG DELIVERY
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
- (2022) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
- (2022) Myrto Moutafi et al. LABORATORY INVESTIGATION
- Targeting the gut and tumor microbiota in cancer
- (2022) Elizabeth M. Park et al. NATURE MEDICINE
- Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
- (2022) José Manuel Pérez-García et al. NEURO-ONCOLOGY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
- (2022) David B. Page et al. npj Breast Cancer
- Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
- (2022) Jian Zhang et al. CLINICAL CANCER RESEARCH
- Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
- (2022) Erika P. Hamilton et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
- (2022) C.A. Powell et al. ESMO Open
- Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
- (2021) Neil T. Conlon et al. BRITISH JOURNAL OF CANCER
- Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
- (2021) Eryn Blass et al. Nature Reviews Clinical Oncology
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
- (2021) Martine Piccart et al. JOURNAL OF CLINICAL ONCOLOGY
- Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2021) Binghe Xu et al. LANCET ONCOLOGY
- Advances in Combining Radiation and Immunotherapy in Breast Cancer
- (2021) Anthony T. Nguyen et al. Clinical Breast Cancer
- Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
- (2021) Yingying Xu et al. Gastric Cancer
- Theranostic Advances in Breast Cancer in Nuclear Medicine
- (2021) Nasim Vahidfar et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
- (2021) Otto Metzger Filho et al. Cancer Discovery
- Antibody‒drug conjugates: Recent advances in linker chemistry
- (2021) Zheng Su et al. Acta Pharmaceutica Sinica B
- The Chemistry Behind ADCs
- (2021) Vesela Kostova et al. Pharmaceuticals
- Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls
- (2021) G. Antonarelli et al. ANNALS OF ONCOLOGY
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
- (2021) C. Saura Manich et al. ANNALS OF ONCOLOGY
- 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
- (2021) S.J. Klempner et al. ANNALS OF ONCOLOGY
- Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
- (2021) Ariella B. Hanker et al. CANCER CELL
- Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
- (2021) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
- (2021) Erica Michelle Stringer-Reasor et al. JOURNAL OF CLINICAL ONCOLOGY
- Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
- (2021) Yasir Y. Elamin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
- (2021) Xichun Hu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
- (2021) Alison M. Schram et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
- (2021) Guy Heinrich Maria Jerusalem et al. JOURNAL OF CLINICAL ONCOLOGY
- The blood–tumour barrier in cancer biology and therapy
- (2021) Patricia S. Steeg Nature Reviews Clinical Oncology
- Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
- (2021) Rosalynd Upton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
- (2021) Faroogh Marofi et al. Frontiers in Oncology
- HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
- (2021) Ilana Schlam et al. npj Breast Cancer
- 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors
- (2021) M.R. Sharma et al. ANNALS OF ONCOLOGY
- Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
- (2021) Pablo Mandó et al. BREAST
- Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
- (2021) Evanthia T. Roussos Torres et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer vaccines for treatment and prevention
- (2021) Mary L. Disis et al. BREAST CANCER RESEARCH AND TREATMENT
- First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
- (2021) Jian Zhang et al. CLINICAL CANCER RESEARCH
- Disitamab Vedotin: First Approval
- (2021) Emma D. Deeks DRUGS
- Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
- (2021) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers
- (2021) Flávia Miranda et al. MOLECULAR BIOLOGY REPORTS
- The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial
- (2021) Tiziana Triulzi et al. Molecular Oncology
- HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
- (2021) Alison E. Smith et al. Nature Communications
- Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions
- (2021) Alma Andersson et al. Nature Communications
- What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
- (2021) Sara Pizzamiglio et al. Cancer Medicine
- Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
- (2021) Christopher Sloas et al. Frontiers in Immunology
- Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
- (2021) Hoyoung M. Maeng et al. Frontiers in Oncology
- The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers
- (2020) A. Yver et al. ANNALS OF ONCOLOGY
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
- (2020) G. Curigliano et al. ANNALS OF ONCOLOGY
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial
- (2020) C.H. Barcenas et al. ANNALS OF ONCOLOGY
- Toll-like Receptors and the Control of Immunity
- (2020) Katherine A. Fitzgerald et al. CELL
- Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
- (2020) Erika Paige Hamilton et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
- (2020) Yeon Hee Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
- (2020) Sara M Tolaney et al. LANCET ONCOLOGY
- Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
- (2020) Anita Kulukian et al. MOLECULAR CANCER THERAPEUTICS
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
- (2020) Jerri C. Caldeira et al. Viruses-Basel
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- The emerging roles of artificial intelligence in cancer drug development and precision therapy
- (2020) Guosheng Liang et al. BIOMEDICINE & PHARMACOTHERAPY
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy
- (2020) Balamurugan Shanmugaraj et al. LIFE SCIENCES
- ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
- (2020) Lillian Skidmore et al. MOLECULAR CANCER THERAPEUTICS
- 525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
- (2020) G. Ku et al. ANNALS OF ONCOLOGY
- Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
- (2020) Arlene Chan et al. Clinical Breast Cancer
- Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
- (2020) Eva Ciruelos et al. CLINICAL CANCER RESEARCH
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis
- (2020) U. Dafni et al. EUROPEAN JOURNAL OF CANCER
- Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- (2020) Antoinette R Tan et al. LANCET ONCOLOGY
- Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study
- (2019) Erika J Crosby et al. CLINICAL CANCER RESEARCH
- CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
- (2019) Deepak Mittal et al. Cancer Immunology Research
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors
- (2019) Tanios Bekaii-Saab et al. CLINICAL CANCER RESEARCH
- T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
- (2019) M Messaoudene et al. ANNALS OF ONCOLOGY
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers
- (2019) Urs B Hagemann et al. CLINICAL CANCER RESEARCH
- Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy
- (2019) Jeffrey C. Kang et al. NATURE BIOTECHNOLOGY
- Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
- (2019) Christian Jackisch et al. JAMA Oncology
- Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
- (2019) Collins et al. Cancers
- Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
- (2019) Claudio Vernieri et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Preclinical Combination Studies of an FGFR2 Targeted Thorium Conjugate and the ATR Inhibitor BAY 1895344
- (2019) Katrine Wickstroem et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Vaccine Therapies for Breast Cancer
- (2019) Erin E. Burke et al. Surgical Oncology Clinics of North America
- The single-cell sequencing: new developments and medical applications
- (2019) Xiaoning Tang et al. Cell and Bioscience
- CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling
- (2019) Hee‐Joo Choi et al. EMBO REPORTS
- Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
- (2019) Afshin Derakhshani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
- (2019) Shengnan Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Breast Cancer Vaccines: Heeding the Lessons of the Past to Guide a Path Forward
- (2019) Cinzia Solinas et al. CANCER TREATMENT REVIEWS
- De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
- (2019) Debu Tripathy et al. ONCOLOGIST
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
- (2019) Francis W. Hunter et al. BRITISH JOURNAL OF CANCER
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
- (2018) Cecile A.W. Geuijen et al. CANCER CELL
- Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
- (2018) Andreas Schneeweiss et al. INVESTIGATIONAL NEW DRUGS
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
- (2018) Luca Gianni et al. LANCET ONCOLOGY
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
- (2018) Sara A Hurvitz et al. LANCET ONCOLOGY
- Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
- (2018) Hans H. Oberg et al. Frontiers in Immunology
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
- (2018) Emiliano Cocco et al. Science Signaling
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
- (2017) Sibylle Loibl et al. EUROPEAN JOURNAL OF CANCER
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
- (2017) Saro H. Armenian et al. JOURNAL OF CLINICAL ONCOLOGY
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
- (2017) Paola A. Betancur et al. Nature Communications
- Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
- (2017) Ji-Yeon Kim et al. Oncotarget
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
- (2017) Andres Lopez-Albaitero et al. OncoImmunology
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
- (2016) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer
- (2016) DJ Slamon et al. CANCER RESEARCH
- Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 pos DCIS Independent of Route: Results of Randomized Selection Design Trial
- (2016) Lea Lowenfeld et al. CLINICAL CANCER RESEARCH
- The development and use of the E75 (HER2 369–377) peptide vaccine
- (2016) Guy T Clifton et al. Future Oncology
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
- (2016) Elizabeth A. Mittendorf et al. Oncotarget
- Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
- (2016) Debora de Melo Gagliato et al. Oncotarget
- Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003:
- (2015) Nikhil Wagle et al. CANCER RESEARCH
- Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy
- (2015) Tarah J. Ballinger et al. Clinical Breast Cancer
- Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
- (2015) L. G. Lum et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
- (2015) D. Meulendijks et al. CLINICAL CANCER RESEARCH
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
- (2015) V. Guarneri et al. ONCOLOGIST
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
- (2014) G. Chen et al. Cancer Immunology Research
- Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients
- (2013) Matthew D. Onsum et al. AMERICAN JOURNAL OF PATHOLOGY
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
- (2013) Srinivas Mamidi et al. Molecular Oncology
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
- (2012) I. Vaz-Luis et al. ANNALS OF ONCOLOGY
- HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
- (2012) Anupama Sharma et al. CANCER
- Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice
- (2012) Victoria Dinkel et al. CANCER RESEARCH
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
- (2012) Erika Hamilton et al. Journal of Translational Medicine
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells
- (2011) Yong Zhao et al. CANCER LETTERS
- Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy
- (2011) Chun Hing Tse et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
- (2011) Rama Krishna Kancha et al. PLoS One
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Quality assessment of HER2 testing by monitoring of positivity rates
- (2011) Harald Choritz et al. VIRCHOWS ARCHIV
- Treatment of HER2-overexpressing breast cancer
- (2010) J. Baselga ANNALS OF ONCOLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
- (2010) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- (2009) I-Tien Yeh et al. MODERN PATHOLOGY
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
- (2008) Stephen Chia et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
- (2008) Ignacio Melero et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started